2-(2-碘苯氧基)乙醇 | 67856-39-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(2-碘苯氧基)乙醇
• 英文名称: 2-(2-iodophenoxy)ethan-1-ol
• 英文别名: 2-iodophenoxyethanol；2-(2-Iodophenoxy)ethanol
• CAS: 67856-39-7
• 化学式: C₈H₉IO₂
• 分子量: 264.063
• InChiKey: ASGZYHAGSOQMOV-UHFFFAOYSA-N

物化性质

• 沸点：
  326.5±22.0 °C(Predicted)
• 密度：
  1.766±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-碘苯氧基)乙醇 在 palladium on activated charcoal potassium phosphate 、 四(三苯基膦)钯 、 硼酸三甲酯 、 氢气 、 叔丁基锂 、 sodium hydride 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 、 xylene 为溶剂， 140.0 ℃ 、101.33 kPa 条件下， 反应 28.25h， 生成 4-[2-(2-Pyrimidin-5-yl-phenoxy)-ethylamino]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carboxylic acid dimethylamide
  参考文献：
  名称：

  N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α₁-Adrenoceptor Antagonists

  摘要：

  Novel arylpiperazines were identified as alpha(1)-adrenoceptor(BR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides,;as well as carboxamides of quinoline, I,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta;a were used as a ''negative screen'' for the test antagonists. Binding to alpha(1)-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g, 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the alpha(1)-AR subtype prevalent in the human lower urinary tract (pA(2) values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the alpha(1D)-AR.

  DOI：

  10.1021/jm970166j
• 作为产物：
  描述：

  Tert-butyl(2-(2-iodophenoxy)ethoxy)dimethylsilane 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 2-(2-碘苯氧基)乙醇
  参考文献：
  名称：

  MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME

  摘要：

  本发明提供了一种新颖的构象定义明确的大环化合物，可以作为生长激素分泌素受体（GHS-R1a及其亚型、异构体和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂，用于治疗和预防一系列医疗状况，包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、骨骼疾病、遗传疾病、过度增生性疾病和炎症性疾病。

  公开号：

  US20080194672A1

文献信息

• Macrocyclic Modulators of the Ghrelin Receptor
  申请人：Ocera Therapeutics, Inc.

  公开号：US20180110824A1

  公开（公告）日：2018-04-26

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新颖的构象定义明确的大环化合物，已经证明是生长激素分泌素受体（GHS-R1a及其亚型、异构体和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂，用于治疗和预防一系列医疗状况，包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、遗传疾病、过度增殖性疾病和炎症性疾病。
• Synthesis of Indolines via a Domino Cu-Catalyzed Amidation/Cyclization Reaction
  作者：Ana Minatti、Stephen L. Buchwald

  DOI：10.1021/ol8008792

  日期：2008.7.3

  A highly efficient one-pot procedure for the synthesis of indolines and their homologues based on a domino Cu-catalyzed amidation/nucleophilic substitution reaction has been developed. Substituted 2-iodophenethyl mesylates and related compounds afforded the corresponding products in excellent yields. No erosion of optical purity was observed when transforming enantiomerically pure mesylates under the

  已经开发了一种基于多米诺铜催化的酰胺化/亲核取代反应合成二氢吲哚及其同系物的高效一锅法。取代的 2-碘苯乙基甲磺酸酯和相关化合物以优异的产率提供了相应的产品。在反应条件下转化对映体纯的甲磺酸盐时，没有观察到光学纯度的降低。
• Access to Indole‐Fused Benzannulated Medium‐Sized Rings through a Gold(I)‐Catalyzed Cascade Cyclization of Azido‐Alkynes
  作者：Luca C. Greiner、Shinsuke Inuki、Norihito Arichi、Shinya Oishi、Rikito Suzuki、Tomohiro Iwai、Masaya Sawamura、A. Stephen K. Hashmi、Hiroaki Ohno

  DOI：10.1002/chem.202101824

  日期：2021.9.9

  Because benzannulated and indole-fused medium-sized rings are found in many bioactive compounds, combining these fragments might lead to unexplored areas of biologically relevant and uncovered chemical space. Herein is shown that α-imino gold carbene chemistry can play an important role in solving the difficulty in the formation of medium-sized rings. Namely, phenylene-tethered azido-alkynes undergo

  因为在许多生物活性化合物中发现了苯并环化和吲哚稠合的中等大小的环，将这些碎片结合起来可能会导致未探索的生物相关区域和未发现的化学空间。本文表明，α-亚氨基金卡宾化学可以在解决中等尺寸环形成困难方面发挥重要作用。即，亚苯基系链的叠氮炔烃通过形成金卡宾中间体进行芳基化环化，得到苯并环化吲哚稠合的中等大小的四环化合物。这些反应允许一系列不同的芳基取代模式，并有效地获得这些原本难以获得的中等大小的环。该研究还证明了半空心形 C-dtbm 配体用于构建九元环的可行性。
• Intermediates for macrocyclic compounds
  申请人：Marsault Eric

  公开号：US09181298B2

  公开（公告）日：2015-11-10

  The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

  本发明涉及一种新型的大环化合物，其化学式为（I），以及其药用可接受的盐、水合物或溶剂化合物：其中R1、R2、R3、R4、R5、R6、n1、m、p、Z1、Z2和Z3如规范中所描述。该发明还涉及化合物的化学式（I），这些化合物是胃动素受体拮抗剂，可用于治疗与该受体相关的疾病以及与胃肠动力功能障碍相关的疾病。
• Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
  申请人：Hoveyda Hamid R.

  公开号：US20110105389A1

  公开（公告）日：2011-05-05

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.

  本发明提供了新型构象定义的大环化合物，已被证明是生长激素分泌素受体（GRLN，生长激素分泌素受体，GHS-R1a及其亚型、异构体和/或变种）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的拮抗剂或逆向激动剂，以及用于治疗和预防一系列医学疾病，包括但不限于代谢和/或内分泌紊乱、肥胖和与肥胖相关的疾病、食欲或进食紊乱、成瘾紊乱、心血管疾病、胃肠道疾病、遗传疾病、过度增殖性疾病、中枢神经系统疾病和炎症性疾病。